Obesity Clinical Trials in Rochester, Minnesota

11 studies are recruiting for obesity in Rochester, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Weight Loss Through Mayo Clinic Diet

   The purpose of study is to evaluate the efficacy of the Mayo Clinic Diet in clinically significant weight loss (>5%) versus usual care. We also wish to evaluate the feasibility, barriers to completion, and sustainability of this intervention at the 24, and 52-week marks. Lastly, we aim to study the…

   Stage

   Not phased

   Ages

   18 to 64

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06862375 on ClinicalTrials.gov

2. The RESET System Pivotal Clinical Trial (Protocol Revision K)

   A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and eff…

   Stage

   Not phased

   Ages

   22 to 65

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   27 in total

   Run by

   Morphic Medical Inc.

   See if you can join NCT04101669 on ClinicalTrials.gov

3. Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

   The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less than 12 years of age, with obesity. Participation in the study will last …

   Stage

   Phase 3

   Ages

   6 to 11

   Site

   Mayo Clinic - PIN, Rochester, Minnesota

   Locations

   82 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07817875 on ClinicalTrials.gov

4. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.

   Stage

   Phase 3

   Ages

   6 to 17

   Site

   Mayo Clinic - PIN, Rochester, Minnesota

   Locations

   116 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06672549 on ClinicalTrials.gov

5. Upper Body Subcutaneous Exosome Release in Response to a Meal in Obesity

   The purpose of this study is to understand the specific outflow and difference between normal weight and volunteers with obesity of upper body subcutaneous adipose tissue in response to a mixed meal challenge by site specific cannulation of the superior epigastric vein. We will characterize the exo…

   Stage

   Not phased

   Ages

   18 to 55

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT07031297 on ClinicalTrials.gov

6. Fibrosis Lessens After Metabolic Surgery

   Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease aff…

   Stage

   Phase 4

   Ages

   18 to 75

   Site

   Mayo Clinic, Rochester, Minnesota

   Locations

   22 in total

   Run by

   The Cleveland Clinic

   See if you can join NCT06374875 on ClinicalTrials.gov

7. Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial

   The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Mayo Clinic, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06770049 on ClinicalTrials.gov

8. Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

   Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.

   Stage

   EARLY_Phase 1

   Ages

   18 to 65

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06416969 on ClinicalTrials.gov

9. Regional Lipolysis Insulin Regulation

   Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.

   Stage

   EARLY_Phase 1

   Ages

   18 to 65

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Run by

   Mayo Clinic

   See if you can join NCT06392854 on ClinicalTrials.gov

10. Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

    The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to an…

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    Mayo Clinic, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07213466 on ClinicalTrials.gov

11. Insulin Regulation of Lipolysis and Lipolysis Proteins

    These studies will define the abnormalities in the adipocyte proteins that are involved in the failure of insulin to suppress lipolysis normally in humans with upper body obesity and will help discover the mechanism by which pioglitazone, a medication used to treat type 2 diabetes and improve insul…

    Stage

    EARLY_Phase 1

    Ages

    18 to 55

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT03866408 on ClinicalTrials.gov